Verrica Pharmaceuticals Faces Nasdaq Delisting Notice
Ticker: VRCA · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00, $5,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, nasdaq
Related Tickers: VRCA
TL;DR
Nasdaq's coming for Verrica's listing, company's scrambling to fix it.
AI Summary
Verrica Pharmaceuticals Inc. announced on January 24, 2025, that it received a notice from The Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options and plans to regain compliance with Nasdaq's listing standards.
Why It Matters
This notice could lead to Verrica Pharmaceuticals' stock being delisted from the Nasdaq, potentially impacting its liquidity and investor confidence.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major stock exchange like Nasdaq poses a significant risk to the company's market presence and investor accessibility.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — The company filing the 8-K
- The Nasdaq Stock Market (company) — The exchange that issued the delisting notice
- January 24, 2025 (date) — Date of the earliest event reported
FAQ
What specific continued listing rule did Verrica Pharmaceuticals fail to meet?
The filing states that Verrica Pharmaceuticals received a notice from The Nasdaq Stock Market indicating a failure to meet continued listing requirements, but it does not specify which particular rule was violated.
What are Verrica Pharmaceuticals' options in response to the delisting notice?
Verrica Pharmaceuticals is currently evaluating its options to regain compliance with Nasdaq's listing standards.
When did Verrica Pharmaceuticals receive this notice?
The earliest event reported in the filing occurred on January 24, 2025.
What is Verrica Pharmaceuticals' principal executive office address?
The principal executive offices of Verrica Pharmaceuticals are located at 44 W. Gay St., Suite 400, West Chester, PA 19380.
What is Verrica Pharmaceuticals' IRS Employer Identification Number?
Verrica Pharmaceuticals' IRS Employer Identification Number is 46-3137900.
Filing Stats: 835 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-01-30 16:16:51
Key Financial Figures
- $1.00 — he Company's common stock was less than $1.00 per share for the previous 30 consecuti
- $5,000 — to submit a Transfer Application and a $5,000 application fee. In addition, the Compa
Filing Documents
- d913894d8k.htm (8-K) — 25KB
- 0001193125-25-017264.txt ( ) — 144KB
- vrca-20250124.xsd (EX-101.SCH) — 3KB
- vrca-20250124_lab.xml (EX-101.LAB) — 18KB
- vrca-20250124_pre.xml (EX-101.PRE) — 11KB
- d913894d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: January 30, 2025 /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer